The combined radiation and chemotherapy administered to the boy at a relatively young age would be expected to cause neurocognitive dysfunction. School problems are common for children treated with craniospinal irradiation (even older children), who should be evaluated and problems addressed promptly to optimize learning.
Introduction
The overall 5-year survival rate for victims of childhood cancer is now approximately 75%. A long-term survivor can be defined arbitrarily as one having no recurrent disease 5 years after diagnosis. Although always at risk for relapse, 92% of cancer patients who are disease-free at 5 years are expected to be alive 15 years after diagnosis. Effort must be focused on health issues that result from the cancer or its treatment. Late effects vary with the primary disease, its location and treatment, and genetic or other underlying medical problems. Many late effects develop slowly and are not evident at the end of therapy. Accordingly, the follow-up of survivors should be tailored to monitor for specific risk factors and should change as time from diagnosis increases (Tables 1 and 2 ). Many of the more serious long-term effects require early recognition and management for the most favorable outcome. A guideline for long-term follow-up of patients who have acute lymphoblastic leukemia (ALL) is provided (Table 3) . Although ALL is the most common malignancy of childhood, the incidence of late effects is relatively low. Late effects of surgery are determined by the specific procedure and are not discussed further. 
Neurocognitive Sequelae
Patients who receive cranial radiation or either methotrexate or cytarabine administered intrathecally or intravenously in high doses are at risk for neurocognitive dysfunction (Tables 1 and 2 ). Most have brain tumors or acute leukemia and require therapy of the central nervous system. Deficits of attention span, short-term memory, speed of mental processing, visual-motor coordination, or sequencing abilities are common. Intellectual decline is more apparent in children treated at a younger age and is proportional to the dose of radiation or intensity and duration of chemotherapy. More subtle cognitive damage may not be evident until academic work becomes more demanding. A formal neuropsychological evaluation should be performed by an experienced professional at the end of therapy if any neurocognitive dysfunction is suspected and then periodically as indicated. Individualized recommendations for school can be made, and the indications and benefits of attention-focusing medications discussed. Hearing loss can result from chemotherapy (primarily cisplatin) or cranial radiation (Tables 1 and 2 ). Cisplatin can cause high-frequency sensorineural hearing loss (Table 2). Conductive hearing loss can occur in patients receiving cranial irradiation because of stimulation of cerumen production that causes impaction of the tympanic canal. Audiograms should be performed if hearing loss is suspected or learning difficulties are encountered.
Cardiotoxicity
Anthracycline use is the most common cause of heart damage in pediatric cancer survivors. The risk for cardiotoxicity increases with higher cumulative doses of anthracyclines and is related to female sex, younger age, trisomy 21, radiation involving the heart, and exposure to alkylating agents. Controversy remains over the maximum safe dose of anthracyclines because toxicity may occur with relatively low doses. In younger children, follow-up is essential regardless of dose. Agents to reduce the risk of cardiac toxicity without compromising effects on the tumor are under study. Screening with echocardiography and electrocardiography should be performed every 1 to 5 years, depending on the cumulative anthracycline dose and other risk factors (Table 4) .
Cardiac radiation can cause chronic pericarditis and may increase the risk of early-onset coronary artery disease (Table 1) . Familial risks, presence of hyperlipidemia, and results of stress testing, when indicated, should be addressed.
Endocrinopathies
Endocrine abnormalities are common late effects and usually can be treated. The pituitary, thyroid, and gonads are affected most. Cranial radiation predisposes patients to growth hormone deficiency. Like most endocrine effects, the degree of damage correlates with the radiation dose. Doses greater than 3,000 cGy usually cause hematology/oncology survivors of childhood cancer growth hormone deficiency, but it can occur with doses as low as 1,800 cGy. Chemotherapy in combination with cranial radiation contributes to growth hormone deficiency. Patients should be monitored for height, weight, body mass index percentiles, and SMR staging, with comparisons made to family patterns. Hypothyroidism can result from radiation of the pituitary (Ͼ3,000 cGy) or the thyroid gland (Ͼ2,000 cGy). Hypothyroidism occurs in up to 50% of patients who received radiation to the thyroid gland and can take years to develop. Female sex, higher radiation doses, and older age are risk factors for hypothyroidism. Free thyroxine and thyroid-stimulating hormone should be monitored yearly. Hyperthyroidism, thyroid nodules, and thyroid cancer also are more likely to develop following thyroid radiation (Table 1) .
Alkylating agents and gonadal radiation can impair fertility and sexual development (Tables 1 and 2 ). Efforts are being made to restrict or omit alkylating agents because they increase the risk of sterility. Unfortunately, they are very effective agents, especially in treating solid tumors. Males treated with alkylators or testicular radiation retain endocrine function at higher doses than females, but spermatogenesis is more sensitive. Younger boys demonstrate less of an effect on sperm production, but prepubertal boys are not spared. Sperm banking should be encouraged in adolescent boys to circumvent the sterilizing effects of therapy.
In females, hormonal function correlates with the potential for fertility. Because of the decreasing number of oocytes, the risk of menstrual irregularities, premature ovarian failure, and infertility increases with older age at treatment. Prepubertal females tolerate high doses of alkylating agents, but high doses of radiation may cause premature ovarian failure, leading to failure to develop secondary sexual characteristics. Adolescent girls often recover gonadal function after therapy, but are at risk for premature menopause, with a decrease in years of potential fertility. Survivors should be monitored with regard to puberty, menses, sexual function, and SMR staging. Luteinizing hormone, follicle-stimulating hormone, and testosterone or estradiol should be measured, with referral to an endocrinologist if indicated.
Secondary Malignancies
The cumulative risk at 20 years for second malignant neoplasms in survivors of pediatric cancer is 3% to 10%, which is 5 to 20 times greater than for the general population. Much of this risk is associated with therapies known to be carcinogenic. Radiation is associated with the development of cancer in the radiation field, notably, breast cancer, thyroid cancer, skin cancers, brain tumors, and most commonly, bone and soft-tissue sarcomas (Table 2). Epipodophyllotoxins (ie, etoposide) and alkylating agents are associated with secondary development of acute myeloid leukemia (Table 2 ). Patients treated with cyclophosphamide have a higher risk of developing bladder cancer (Table 2) . For some, a genetic defect results in an increased risk for specific cancers.
Certain diseases require special mention. Secondary malignancies are particularly common in survivors of Hodgkin disease and include acute myeloid leukemia, nonHodgkin lymphoma, breast cancer, and other solid tumors. The risk for some of these malignancies increases with time. Children who have the genetic form of retinoblastoma, which includes all who have bilateral disease and about 10% of children who have unilateral disease, have a 50% chance of developing a secondary malignancy, regardless of whether they are treated. Hepatoblastoma has been associated with familial polyposis coli, and survivors should be screened for colon cancer.
Survivors should be informed of their risks for developing secondary cancers and should be evaluated yearly by a clinician familiar with their treatment and risks.
Psychosocial Effects
Efforts recently have focused on the psychosocial impact of cancer and its treatment on survivors. In 1994, "learning that one/one's child has a life-threatening disease" was included in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edition as an event sufficiently traumatic to precipitate posttraumatic stress disorder (PTSD). The traumatic impact of being given the diagnosis and of experiencing treatment that can include painful, invasive procedures, frequent hospitalizations, separations from family and friends, and fear of the unknown is great. It is estimated hematology/oncology survivors of childhood cancer that PTSD occurs in about 5% to 20% of survivors of childhood cancer and in 6% to 25% of their mothers. Recent data suggest that cancer-related PTSD emerges in young adulthood and may affect the achievement of developmental milestones. Young adulthood is a time of increased vulnerability and major psychosocial challenges that may require, perhaps for the first time, a focus on the effects of cancer and its treatment. The impact seems to be associated more with survivors' perceptions of treatment and its effects rather than with more objective medical data. Counseling can help survivors and their families work through these issues in a healthy manner. A recent study showed that a large proportion of survivors were functioning well and leading normal lives, but there was a subgroup that was less likely to complete high school and more likely to have learning disabilities. The percentage of employed survivors was lower than the percentage of employed controls. Survivors had lower rates of marriage and parenthood. Poor adjustment, depression, and diminished functioning in the area of social contacts and friendships may account for some of these findings.
Denial of insurance coverage and other examples of discrimination are concerns for the survivor. It may be difficult to obtain life and health insurance. Entrance into the military has been denied. Job discrimination is much less common now that laws are in place to protect survivors. Cancer survivors have addressed such issues by working with national organizations such as the Candlelighters or the National Coalition for Cancer Survivorship.
Summary
Health-promoting behaviors for cancer survivors should be stressed and evaluations limited to those that are cost-effective and have a defined intervention. All survivors of childhood cancer should receive regular medical care throughout life from a physician who is aware of their treatment and is comfortable with risk-based monitoring for specific late effects. Most pediatric oncology programs can provide or assist in this care. Survivors now are reaching an age when adult follow-up is more appropriate. Therefore, pediatricians, internists, and family practitioners all are encouraged to take a more active role in caring for cancer survivors and educating themselves about the risks for late effects.
